Athira Shifts Focus to ALS Drug Following Alzheimer’s Trial Flop
Overview of Athira Pharma's Transition
Athira Pharma has made significant changes in its research focus. After the disappointing results from its Alzheimer’s drug fosgonimeton in the LIFT-AD trial, the company is shifting its attention to developing ATH-1105, an ALS treatment. This strategic decision also includes a substantial workforce reduction, aiming to streamline operations and focus resources efficiently.
Impact of the Alzheimer’s Trial Results
- The LIFT-AD trial did not meet its endpoints, leading to reevaluation of drug development strategies.
- Athira plans to cut approximately 70% of its workforce to conserve resources.
- Expected savings from the layoffs are projected to be around $13.4 million.
Looking Ahead: The ALS Drug Development
Athira's renewed focus on ATH-1105 represents a critical pivot towards addressing unmet medical needs in ALS treatment. The healthcare community is keenly observing this transition as it could potentially lead to breakthroughs in the neurodegenerative sector.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.